New data has indicated that Jardiance (empagliflozin) is capable of reducing the risk of heart failure and cardiovascular death when added to the regimens of patients living with type two diabetes (T2D), indications that came as part of the results of a test comparing the actual administration of the drug to the administration of placebo.
The data was presented at the recent 2015 Scientific Sessions of the American Heart Association in Orlando, Florida.
Jardiance is a product of Boehringer Ingelheim Pharmaceuticals, Inc., and Eli Lilly and Co.
"Cardiovascular disease, including heart failure, is the leading cause of death associated with diabetes," Dr. Silvio Inzucchi of Yale School of Medicine said. "People with diabetes are two to three times more likely to develop heart failure than those individuals without diabetes. We need treatments that can help reduce the high rates of heart failure — and the resulting hospitalizations and deaths — in this population."
Jardiance was also shown to reduce the rates of hospitalization for heart failure in T2D patients.
"To date, no glucose-lowering medication has been shown to reduce the risk of hospitalization for heart failure or death from heart failure in a cardiovascular outcomes study," Hans-Juergen Woerle, global vice president medicine of Boehringer Ingelheim, said. "These results with Jardiance show the importance of continuing to advance research that will help our understanding of how to manage and mitigate the risk of cardiovascular disease in people with type two diabetes."
The testing for Jardiance was long-term, conducted at multiple locations, randomized and double-blind and involved more than 7,000 patients from 42 countries with T2D. More details are available at www.fda.gov/medwatch.
Boehringer Ingelheim was founded in 1885 by Albert Boehringer in Ingelheim am Rhein.
